AIM ImmunoTech, Inc. (AIM)
0.2297
0.00 (0.00%)
USD |
NYAM |
Sep 08, 16:00
0.2297
0.00 (0.00%)
Pre-Market: 09:09
AIM ImmunoTech Shareholders Equity (Quarterly) : 7.744M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.744M |
| March 31, 2026 | 2.125M |
| December 31, 2025 | -9.783M |
| September 30, 2025 | -6.077M |
| June 30, 2025 | -6.546M |
| March 31, 2025 | -3.857M |
| December 31, 2024 | -1.322M |
| September 30, 2024 | 2.912M |
| June 30, 2024 | 6.102M |
| March 31, 2024 | 4.826M |
| December 31, 2023 | 10.23M |
| September 30, 2023 | 22.60M |
| June 30, 2023 | 30.14M |
| March 31, 2023 | 34.99M |
| December 31, 2022 | 38.47M |
| September 30, 2022 | 42.70M |
| June 30, 2022 | 48.78M |
| March 31, 2022 | 53.30M |
| December 31, 2021 | 56.88M |
| September 30, 2021 | 62.05M |
| June 30, 2021 | 65.53M |
| March 31, 2021 | 70.97M |
| December 31, 2020 | 61.29M |
| September 30, 2020 | 61.11M |
| June 30, 2020 | 46.99M |
| Date | Value |
|---|---|
| March 31, 2020 | 35.11M |
| December 31, 2019 | 13.44M |
| September 30, 2019 | 13.84M |
| June 30, 2019 | 6.548M |
| March 31, 2019 | 3.93M |
| December 31, 2018 | 5.174M |
| September 30, 2018 | 6.439M |
| June 30, 2018 | 9.096M |
| March 31, 2018 | 10.20M |
| December 31, 2017 | 8.703M |
| September 30, 2017 | 10.04M |
| June 30, 2017 | 10.33M |
| March 31, 2017 | 12.95M |
| December 31, 2016 | 15.50M |
| September 30, 2016 | 16.63M |
| June 30, 2016 | 17.49M |
| March 31, 2016 | 18.41M |
| December 31, 2015 | 20.37M |
| September 30, 2015 | 23.17M |
| June 30, 2015 | 26.76M |
| March 31, 2015 | 26.97M |
| December 31, 2014 | 25.00M |
| September 30, 2014 | 26.36M |
| June 30, 2014 | 29.37M |
| March 31, 2014 | 31.99M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 12.73M |
| Total Liabilities (Quarterly) | 4.987M |
| Debt to Equity Ratio | 0.5063 |
| Current Ratio | 2.109 |
| Net Debt Paydown Yield | -3.40% |